Anti-Obesity Drugs - Trends & Opportunities Worldwide

Anti-Obesity Drugs - Trends & Opportunities Worldwide published by BizAcumen, Inc. in November, 2009. This report consists of Pages: 286 and the price starts from US $ 2995.

Introduction

Abstract

The world today is facing an acute crisis of over-weightiness and its more advance form, obesity. The need to combat obesity may be understood from the fact that it gives rise to life threatening ailments such as heart attack, hypertension, diabetes and certain types of cancer. Obesity prevalence translates to wider opportunities for drug companies, as there exists a huge market for highly efficacious and novel anti-obesity drugs. As such, major proportion of currently available drugs does not meet existing requirements for safety profile and efficacy.

These and other market data and trends are presented in "Anti-Obesity Drugs: Trends & Opportunities Worldwide" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Table of Contents

1. METHODOLOGY

• Study Reliability and Reporting Limitations
• Disclaimers
• Quantitative Techniques & Reporting Level

2. GLOBAL MARKET OVERVIEW AND OUTLOOK

• Factors Influencing the Market
• Obesity - A Global Epidemic
• Trends and Issues
  • Obesity: An Unmet Medical Need
  • Rising Demand for Obesity Therapeutics
  • Barriers to Development of Effective Drugs
  • New Research Aids in Discovery of Novel Drugs
  • Growing Problem of Obesity in Asia Particularly China

3. COMPETITION

• Roche Leads the Race
• Competition Grows with Pipeline Drugs
  • Current Anti-Obesity Drugs in Pipeline: 2008

4. PRODUCT FACTS

• Diagnosis of Obesity
  • BMI Classification
  • Waist Circumference and BMI
• Causes of Obesity
  • Select causes of obesity
• Risks Associated with Obesity
• Obesity Treatment
• Review of Available Drugs
  • Phentermine
  • Sibutramine
  • Orlistat
    • Anti-obesity Drugs, Brands and Mechanism of Action

5. CORPORATE DEVELOPMENTS

• Pfizer Halts CP-945, 598 Development
• Shionogi to Acquire Sciele Pharma
• Anthill Inks Agreement with Zafgen
• EMEA Suspends Acomplia
• GlaxoSmithKline to Sell Alli as OTC Drug
• Sanofi-Aventis to Market Acomplia in UK
• Orexigen Receives 4th US Patent for Contrave
• BELLUS Health to Acquire Innodia
• Ore Secures License to Develop Romazarit
• GlaxoSmithKline Receives FDA Approval for Orlistat
• Pfizer Receives Approval for Slentrol
• GlaxoSmithKline Secures Licensing Rights of Orlistat
• Pfizer Collaborates with Bristol-Myers Squibb
• Takeda Collaborates with LG Life Sciences
• Takeda to Acquire Paradigm
• Sanofi-Aventis Secures Reimbursement Status for Acomplia
• AstraZeneca Inks Agreement with Palatin Technologies
• Switzerland Includes Acomplia in Reimbursement List
• Allergan Pockets EndoArt
• Sanofi-Aventis Receives Approval for Acomplia in Brazil
• Biocon Inks MoU with Neopharma
• Aurigene Partners with Forest Laboratories
• Sanofi-Aventis Receives Swiss Approval for Acomplia
• Zydus Cadila Introduces Slimona
• Torrent Introduces Rimoslim
• Genaera Initiates First Human Trial of Trodusquemine
• Neurogen Completes First Trial of NGD-4715
• Alizyme Secures USFDA Approval for Cetilistat Trials
• GW Pharma to Start Human Trials of New Anti Obesity Drug
• Epix Completes Phase Ib Trial of PRX-07034
• 7TM Pharma Starts Phase I/II Trial of TM30339

6. MAJOR PLAYERS

• Abbott Laboratories (US)
• Alizyme Plc (UK)
• Amylin Pharmaceuticals, Inc. (US)
• AstraZeneca Plc (UK)
• F. HOFFMANN-LA ROCHE LTD. (Switzerland)
• GlaxoSmithKline Plc (UK)
• Sanofi-Aventis SA (France)
• SuperGen, Inc. (USA)
• Takeda Pharmaceutical Company Limited (Japan)
• VIVUS, Inc. (US)

7. GLOBAL MARKET ANALYTICS

8. THE UNITED STATES

• Market Overview
  • Obesity Catching Them Young
  • New Drugs to Rule the Market
  • 37 States Experience Increase in Adult Obesity Rate
• Statistical Data
• Reimbursement Scenario
• Regulatory Environment
  • Insufficient Regulatory and Enforcement Laws
• Obesity and Related Ailments: Burden on Societal and Economic Cost
• Competition

9. EUROPE

• a. France
• b. Germany
• c. Italy
• d. The United Kingdom
• e. Rest of Europe

10. REST OF WORLD

• Brief Review of Select Regions
  • Canada
  • Asia-Pacific
    • Australia
    • China
    • India
      • Drugs Under Development by Indian Companies
    • Japan
    • Korea
      • Use of Diet Pills Lack Proper Monitoring
    • New Zealand

Related Reports